PTN Palatin Technologies
- 1.8610
- -0.0290-1.53%
Palatin Technologies News
Buy Rating Affirmed for Palatin Technologies Following Successful Phase 3 Trial of PL9643 for Dry Eye Disease
Maintained Buy Rating on Palatin Technologies Amid Promising Clinical Results and Future Prospects
Analysts Offer Insights on Healthcare Companies: Palatin Technologies (PTN) and Opko Health (OPK)
Buy Rating Affirmed on Palatin Technologies for Promising Pipeline and Strategic Market Positioning
Palatin Techs Analyst Ratings
Optimistic Buy Rating for Palatin Technologies Backed by Strong Clinical Pipeline and Strategic Initiatives
Optimistic Outlook for Palatin Technologies: A Comprehensive Buy Rating Based on Strong Clinical Pipeline and Upcoming Milestones
Analysts Offer Insights on Healthcare Companies: Liquidia Technologies (LQDA), Henry Schein (HSIC) and Palatin Technologies (PTN)
Analysts Are Bullish on Top Healthcare Stocks: Bioventus (BVS), Palatin Technologies (PTN)
Analysts Offer Insights on Healthcare Companies: Illumina (ILMN), Palatin Technologies (PTN) and Medtronic (MDT)
Analysts Offer Insights on Healthcare Companies: Urogen Pharma (URGN), Palatin Technologies (PTN) and ProKidney (PROK)
Palatin Technologies Receives Buy Rating: F1Q24 Results Surpass Expectations and MELODY-1 Trial Shows Promising Progress
Promising Preclinical Data Bolsters Buy Rating for Palatin Technologies: PL8177's Potential in Ulcerative Colitis Treatment
HC Wainwright & Co. Reiterates Buy on Palatin Techs, Maintains $70 Price Target
Palatin Techs Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Palatin Techs, Maintains $70 Price Target
Palatin Techs Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Palatin Techs, Maintains $70 Price Target
Palatin Techs Analyst Ratings
H.C. Wainwright Remains a Buy on Palatin Technologies (PTN)
Analysis
Price Target
No Data
